open
webcast resource

Debate: Targeted therapy in MS: Should we aim at B or T lymphocytes? B cells

Isolated Syndromes and Therapy

April 13, 2013 | Length: 16:40 min


Infos

Congress:The 7th World Congress on Controversies in Neurology (CONy)
Presenter:A. Bar-Or
Description:

TARGETED THERAPY IN MS: SHOULD WE AIM AT B OR T LYMPHOCYTES? B CELLS Amit Bar-Or Canada
Though MS has been traditionally viewed as a T cell mediated disease, selective B cell depletion has been demonstrated to substantially decrease new CNS lesions and clinical relapses, underscoring an important contribution of B cells to MS disease activity. The treatment effect does not appear to be explained exclusively on the basis of eliminating CNS auto-reactive antibodies, which highlights the increasingly appreciated antibody-independent mechanism(s) of B cell contribution, to both normal immune responses, as well as to autoimmune diseases including MS. We will consider the substantial progress that has been made in understanding how B cells contribute to MS and, in particular, how functionally distinct B cell subsets interact with other immune responses, contributing to MS disease processes at different disease stages and in particular anatomical compartments.

Category: Neurology; Multiple Sclerosis; treatment;